ライフサイエンスコーパス: acute myocardial infarction

1 ersus established cardiac risk factors after acute myocardial infarction.

2 l deficiency of hepcidin and challenged with acute myocardial infarction.

3 y DNR affected hospital quality measures for acute myocardial infarction.

4 beta inhibition has beneficial effects after acute myocardial infarction.

5 o locally regulate cardiac homeostasis after acute myocardial infarction.

6 incident congestive heart failure (CHF) and acute myocardial infarction.

7 urs in patients with cardiogenic shock after acute myocardial infarction.

8 utic hypothermia for cardiogenic shock after acute myocardial infarction.

9 patients with cardiogenic shock complicating acute myocardial infarction.

10 tablished among a sample of 60 patients with acute myocardial infarction.

11 omen are at highest risk after discharge for acute myocardial infarction.

12 ing 30-day risk-standardized mortality after acute myocardial infarction.

13 e as potential immunomodulatory treatment in acute myocardial infarction.

14 ctive study of patients hospitalized with an acute myocardial infarction.

15 or hospital admission of those who died from acute myocardial infarction.

16 ality indicators (QIs) for the management of acute myocardial infarction.

17 nd mitochondrial function in swine models of acute myocardial infarction.

18 ntribute to reducing the mortality burden of acute myocardial infarction.

19 ould mitigate the risk of plaque rupture and acute myocardial infarction.

20 about deaths and hospital admissions due to acute myocardial infarction.

21 cular events, particularly heart failure and acute myocardial infarction.

22 ably quantify AAR and final IS in reperfused acute myocardial infarction.

23 d cell deficiency of IDO and challenged with acute myocardial infarction.

24 hock (CS) as the most severe complication of acute myocardial infarction.

25 ins (cTns) are the cornerstone of diagnosing acute myocardial infarction.

26 between Staphylococcus aureus infection and acute myocardial infarction.

27 phylactic reaction, acute kidney injury, and acute myocardial infarction.

28 subclinical hypothyroidism in patients with acute myocardial infarction.

29 ucially involved in cardiac remodeling after acute myocardial infarction.

30 ath within 1 year of hospitalization with an acute myocardial infarction.

31 patients with cardiogenic shock complicating acute myocardial infarction.

32 r heart failure, 1.76 (95% CI 1.51-2.05) for acute myocardial infarction, 1.78 (95% CI 1.53-2.07) for

33 ogenic shock (CS), 31% had CS not related to acute myocardial infarction, 11% had mixed shock, and 22

34 here were sustained decreases in PAC use for acute myocardial infarction (20.0 PACs placed per 1000 a

35 additional criteria required for spontaneous acute myocardial infarction (280/397, 71%) versus those

36 Acute myocardial infarction (50%) was the main cause of

37 1995 to 2015, including 14 423 patients with acute myocardial infarction (59% STEMI) admitted to card

38 ation of Risk Factors in Older Patients With Acute Myocardial Infarction)-a prospective observational

39 was present in individuals with a history of acute myocardial infarction, a disease state linked to p

40 ardiac troponin for accelerated diagnosis of acute myocardial infarction: a systematic review and met

41 in 28 days of being in hospital follow a non-acute myocardial infarction admission as follow an acute

42 myocardial infarction admission as follow an acute myocardial infarction admission.

43 ance imaging, adjusted for age, sex, type of acute myocardial infarction, affected coronary artery te

44 onclusions In cardiogenic shock complicating acute myocardial infarction, all-cause mortality is simi

45 nts; median 10.7 y follow-up; 648 deaths) or acute myocardial infarction (AMI) (3670 patients; median

46 s investigating the effect of MSC therapy in acute myocardial infarction (AMI) and chronic ischemic c

47 dence of major cardiovascular events such as acute myocardial infarction (AMI) and congestive heart f

48 ffects of PM(2.5) on the risks of developing acute myocardial infarction (AMI) and dying from cardiov

49 ociated with reduced 30-day readmissions for acute myocardial infarction (AMI) and heart failure (HF)

50 Readmission rates after acute myocardial infarction (AMI) and heart failure (HF)

51 esidential green spaces and the incidence of acute myocardial infarction (AMI) and heart failure (HF)

52 tal defect (VSD) is a lethal complication of acute myocardial infarction (AMI) and is often associate

53 isk-standardized mortality rates (RSMRs) for acute myocardial infarction (AMI) are calculated for Med

54 missions among older adults hospitalized for acute myocardial infarction (AMI) are costly and difficu

55 nd cTnT for early diagnosis and prognosis of acute myocardial infarction (AMI) are presented.

56 k-adjusted 30-day home time in patients with acute myocardial infarction (AMI) as a hospital-level pe

57 We examined the short-term risk of acute myocardial infarction (AMI) associated with drugs

58 care units (CICUs) have primarily focused on acute myocardial infarction (AMI) complicated by cardiog

59 Despite advances in treatment, mortality in acute myocardial infarction (AMI) complicated by cardiog

60 Acute myocardial infarction (AMI) complicated by cardiog

61 ic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pa

62 ity cardiac troponin-T (hs-cTnT) in a 1-hour acute myocardial infarction (AMI) exclusion algorithm.

63 ctive therapies into the clinical setting of acute myocardial infarction (AMI) for patient benefit ha

64 emergency department patients with possible acute myocardial infarction (AMI) has been shown to effe

65 nts on dialysis revealed that mortality from acute myocardial infarction (AMI) has decreased, whereas

66 Reducing hospital readmission after acute myocardial infarction (AMI) has the potential to b

67 Patients on dialysis who have an acute myocardial infarction (AMI) have an exceedingly po

68 In recent decades, the rates of incident acute myocardial infarction (AMI) have declined in the U

69 Young women (</=55 years of age) with acute myocardial infarction (AMI) have higher mortality

70 Older adults with acute myocardial infarction (AMI) have higher prevalence

71 f sex-based differences in older adults with acute myocardial infarction (AMI) have yielded mixed res

72 iac events (MACE) in patients with suspected acute myocardial infarction (AMI) is an unmet clinical n

73 Specifically, a fast rule-in or -out of acute myocardial infarction (AMI) is mandatory to improv

74 The diagnosis of acute myocardial infarction (AMI) is missed more frequen

75 Depression among patients with acute myocardial infarction (AMI) is prevalent and assoc

76 emergency department discharge diagnosis of acute myocardial infarction (AMI) or stroke using Intern

77 However, in acute myocardial infarction (AMI) patients, higher admis

78 The role of left atrial (LA) performance in acute myocardial infarction (AMI) remains controversial.

79 The early detection of acute myocardial infarction (AMI) upon the onset of ches

80 (HDs) and 14 plasma samples of patients with acute myocardial infarction (AMI) was carried out with s

81 /angiotensin receptor blockers (ACEI/ARB) in acute myocardial infarction (AMI) were largely conducted

82 For acute myocardial infarction (AMI) without heart failure

83 an quantify the area-at-risk (AAR) following acute myocardial infarction (AMI), and has been used to

84 ay readmission rates for heart failure (HF), acute myocardial infarction (AMI), and pneumonia.

85 ry disease (CAD) and its major complication, acute myocardial infarction (AMI), are the leading cause

86 All-cause mortality, acute myocardial infarction (AMI), ischemic stroke (IS),

87 s on individual process of care measures for acute myocardial infarction (AMI), little is known about

88 e), defined as in-hospital, all-cause death, acute myocardial infarction (AMI), or acute ischemic str

89 rity levels on this outcome, specifically on acute myocardial infarction (AMI), remains unexplored.

90 Background After acute myocardial infarction (AMI), reperfusion injury is

91 In patients with shock after acute myocardial infarction (AMI), the optimal level of

92 and increasing attention to young women with acute myocardial infarction (AMI), who represent an extr

93 l-to-lymphocyte ratio (NLR) in patients with acute myocardial infarction (AMI).

94 management of older patients presenting with acute myocardial infarction (AMI).

95 iRs) are released into the circulation after acute myocardial infarction (AMI).

96 ant role in the development and prognosis of acute myocardial infarction (AMI).

97 markers for diagnosing myocardial injury and acute myocardial infarction (AMI).

98 nflammatory drugs (NSAIDs) use could trigger acute myocardial infarction (AMI).

99 ins (cTn) and is released more rapidly after acute myocardial infarction (AMI).

100 a-blockers and statins are recommended after acute myocardial infarction (AMI).

101 nset of platelet inhibition in patients with acute myocardial infarction (AMI).

102 cTnT) are sometimes used to rapidly rule out acute myocardial infarction (AMI).

103 ation in the first month after discharge for acute myocardial infarction (AMI).

104 Type 2 diabetes predicts outcome following acute myocardial infarction (AMI).

105 not been confirmed in patients with a recent acute myocardial infarction (AMI).

106 mprove management of patients with suspected acute myocardial infarction (AMI).

107 omplexes and a pivotal biochemical marker of acute myocardial infarction (AMI).

108 e oxygenation (ECMO) is increasingly used in acute myocardial infarction (AMI); however, there are li

109 an failure in cardiogenic shock complicating acute myocardial infarction (AMI-CS).

110 heart failure, 0.45 [95% CI, 0.42 to 0.47]; acute myocardial infarction [AMI], 0.37 [CI, 0.35 to 0.4

111 n, hospital admission for unstable angina or acute myocardial infarction [AMI], 30-day readmission af

112 A total of 26 379 patients with acute myocardial infarction and cardiac arrest (5619 in

113 lization files, we identified discharges for acute myocardial infarction and cardiac arrest January 2

114 arization, and mortality among patients with acute myocardial infarction and cardiac arrest.

115 c cardioplegic arrest is only a surrogate of acute myocardial infarction and confounded by the choice

116 ysis in bone marrow cells from patients with acute myocardial infarction and detected increased sulfa

117 117 foods with coronary heart disease risk (acute myocardial infarction and fatal coronary heart dis

118 l risk factors were at target, with risk for acute myocardial infarction and heart failure hospitaliz

119 may lead to better prevention of stroke from acute myocardial infarction and heart failure.

120 n of gap junctions have been associated with acute myocardial infarction and heart failure.

121 The relationship between acute myocardial infarction and infection was recognised

122 n two (1%) patients in the radium-223 group (acute myocardial infarction and interstitial lung diseas

123 ogenic Shock), patients with CS complicating acute myocardial infarction and multivessel coronary art

124 omen and men presenting with CS complicating acute myocardial infarction and multivessel coronary art

125 Among patients with acute myocardial infarction and multivessel disease, mul

126 tient and outpatient PCI, as well as PCI for acute myocardial infarction and nonacute myocardial infa

127 ies were larger, treating more patients with acute myocardial infarction and performing more PCIs tha

128 reas they had less often history of previous acute myocardial infarction and smoking.

129 he expression of hepcidin was elevated after acute myocardial infarction and the specific deletion of

130 arch Investigating Underlying Disparities in Acute Myocardial Infarction) and PREMIER (Prospective Re

131 mplications of atherosclerosis, in ischemic (acute myocardial infarction), and nonischemic injury to

132 ed 706 patients who had multivessel disease, acute myocardial infarction, and cardiogenic shock to on

133 125 231 hospitalizations for heart failure, acute myocardial infarction, and pneumonia, respectively

134 or patients hospitalized with heart failure, acute myocardial infarction, and pneumonia, the three co

135 ation and a composite endpoint of mortality, acute myocardial infarction, and stroke.

136 e-specific events: congestive heart failure, acute myocardial infarction, and stroke.

137 anned readmissions after hospitalization for acute myocardial infarction are among the leading causes

138 Hospitalizations after acute myocardial infarction are commonly underreported i

139 Consequently, early signals of an imminent acute myocardial infarction are likely to be found by pl

140 ion strategies, morbidity and mortality from acute myocardial infarction are still substantial.

141 l infarction diagnosis but went on to die of acute myocardial infarction as the underlying cause of d

142 Intravenously administered MSCs for acute myocardial infarction attenuate the progressive de

143 in-hospital outcomes of patients treated for acute myocardial infarction before and after a hospital

144 h and return to pre-infarct activities after acute myocardial infarction, but the trial lacked statis

145 tween the two, and the overall management of acute myocardial infarction can be reviewed for simplici

146 d data on how sex influences the outcomes of acute myocardial infarction-cardiogenic shock (AMI-CS) i

147 aluating regional disparities in the care of acute myocardial infarction-cardiogenic shock (AMI-CS).

148 subo syndrome (TTS) generally presents as an acute myocardial infarction characterized by severe left

149 In patients with acute myocardial infarction, circumferential strain pred

150 ory support devices are increasingly used in acute myocardial infarction complicated by cardiogenic s

151 The management of patients with acute myocardial infarction complicated by cardiogenic s

152 a mean age of 69.6+/-12.5 years experienced acute myocardial infarction complicated by CS.

153 and clinical outcomes in 7195 subjects with acute myocardial infarction complicated by reduced left

154 ly administered off-the-shelf early after an acute myocardial infarction, comply with stringent crite

155 r older admitted for five medical diagnoses (acute myocardial infarction, congestive heart failure, s

156 ion is available on how primary and comorbid acute myocardial infarction contribute to the mortality

157 INTERPRETATION: As many acute myocardial infarction deaths occurring within 28 d

158 A substantial proportion of patients with acute myocardial infarction develop clinical heart failu

159 x groups) and case-fatality rate for primary acute myocardial infarction diagnosed during the first p

160 counter or during subsequent encounters, and acute myocardial infarction diagnosed only as a comorbid

161 s of admission in people who did not have an acute myocardial infarction diagnosis but went on to die

162 rtality among patients who were admitted for acute myocardial infarction (difference-in-differences e

163 An elevated score predicted incident acute myocardial infarction during 3.6 years of follow u

164 ned readmissions, in-hospital mortality, and acute myocardial infarction during follow-up.

165 entify all primary and comorbid diagnoses of acute myocardial infarction during hospital stay and the

166 ower risk of death after hospitalization for acute myocardial infarction during the full follow-up pe

167 of-concept of efficacy of IL-4 treatment for acute myocardial infarction, encouraging its further dev

168 ivity Troponin-T Assay for Rapid Rule-Out of Acute Myocardial Infarction) evaluated high-sensitivity

169 fibrillation, 7,727 heart failure, and 2,809 acute myocardial infarction events.

170 The NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction) examined the effects of NAC

171 th resulting from all causes, fatal/nonfatal acute myocardial infarction, fatal/nonfatal stroke, and

172 emiological trends, and modern management of acute myocardial infarction, focusing on the recent adva

173 zerland) Plus Registry enrolls patients with acute myocardial infarction from 83 hospitals in Switzer

174 term MINOCA (incorporating the definition of acute myocardial infarction from the newly released "Fou

175 Heart failure and acute myocardial infarction had 29% and 35% fewer cultur

176 Patients with comorbid diagnoses of acute myocardial infarction had two to three times the c

177 decades, the holy grail in the treatment of acute myocardial infarction has been the mitigation of l

178 Acute myocardial infarction has traditionally been divid

179 rd rate ratio for women versus men, 1.10 for acute myocardial infarction; hazard rate ratio, 1.04 for

180 Risk of all-cause mortality, acute myocardial infarction, heart failure hospitalizati

181 tients who were admitted to the hospital for acute myocardial infarction, heart failure, or pneumonia

182 utcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) clinical tria

183 stimate the relative risks of three primary (acute myocardial infarction, hospitalisation for heart f

184 hy, and by primary CR-qualifying event type (acute myocardial infarction hospitalization; coronary ar

185 Among 507 672 patients with acute myocardial infarction hospitalized at these instit

186 an angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0.84, 95% CI 0.75-0.95),

187 5% confidence interval (CI): 1.02, 1.05) and acute myocardial infarction (HRIQR = 1.05, 95% CI: 1.02,

188 ce of ischemic events in patients with prior acute myocardial infarction in a large phase III clinica

189 iation between fire suppression activity and acute myocardial infarction in firefighters.

190 haracteristics, treatments, and outcomes for acute myocardial infarction in France between 1995 and 2

191 ury vs heart failure, pneumonia, stroke, and acute myocardial infarction in older adults between 2008

192 t can be used to predict the risk of a fatal acute myocardial infarction in such patients, which can

193 ncrease the risk of sudden cardiac death and acute myocardial infarction in susceptible people.

194 The AMIS (Acute Myocardial Infarction in Switzerland) Plus Registr

195 sepsis in the intravenous infusion group and acute myocardial infarction in the fixed-dose combinatio

196 inal multicenter cohort study of people with acute myocardial infarction in the United States, querie

197 %) of 446 744 admissions with a diagnosis of acute myocardial infarction, in the second or later phys

198 Patients with acute myocardial infarction including ST-segment elevati

199 Heart failure following acute myocardial infarction is a leading cause of death

200 Subclinical hypothyroidism in patients with acute myocardial infarction is associated with poor prog

201 Acute myocardial infarction is primarily due to coronary

202 engineered fibroblasts into a mouse model of acute myocardial infarction led to improved cardiac func

203 M is a 55 year-old man who suffers an acute myocardial infarction (MI) and undergoes coronary

204 The identification of patients with acute myocardial infarction (MI) at risk of subsequent l

205 Acute myocardial infarction (MI) can occur from increase

206 Acute myocardial infarction (MI) elicits an inflammatory

207 ital treatment and outcomes of patients with acute myocardial infarction (MI) have been described, bu

208 ls of bone marrow cell-based therapies after acute myocardial infarction (MI) have produced mostly ne

209 gf was shown to mediate cardiac repair after acute myocardial infarction (MI) in mice.

210 Recent studies reported an increased risk of acute myocardial infarction (MI) in PPI users vs non-use

211 Left atrial (LA) remodeling after an acute myocardial infarction (MI) is poorly characterized

212 233 US hospitals within 1 year of the index acute myocardial infarction (MI) of 12365 patients enrol

213 Acute myocardial infarction (MI) provokes an inflammator

214 A total of 1,230 patients with acute myocardial infarction (MI) treated with primary pe

215 Acute myocardial infarction (MI) triggers a local and sy

216 ategies significantly reduce mortality after acute myocardial infarction (MI), a large number of pati

217 Primary outcomes were acute myocardial infarction (MI), acute cerebrovascular

218 chemic cardiovascular diseases, particularly acute myocardial infarction (MI), is one of the leading

219 lmark and the primary therapeutic target for acute myocardial infarction (MI), multiple other mechani

220 ed relative to the primary outcome of death, acute myocardial infarction (MI), or hospitalization for

221 o identify patients at low and high risk for acute myocardial infarction (MI).

222 is the most common long-term complication of acute myocardial infarction (MI).

223 ac rupture is a major lethal complication of acute myocardial infarction (MI).

224 s (excess readmission ratio [ERR] > 1) after acute myocardial infarction (MI).

225 omplexity from the acute to chronic phase of acute myocardial infarction (MI).

226 protective against complications related to acute myocardial infarction (MI).

227 ary intervention in patients presenting with acute myocardial infarction, multivessel disease, and ca

228 ll patients aged 40 to 85 presenting with an acute myocardial infarction (n=181 696; 5.7% dog ownersh

229 30), intracerebral haemorrhage (n=3496), and acute myocardial infarction (n=2958); men who reported d

230 vascular diagnoses such as heart failure and acute myocardial infarction, need frequently arises for

231 primary outcome was a composite of nonfatal acute myocardial infarction, nonfatal stroke, or cardiov

232 so calculated what proportion of deaths from acute myocardial infarction occurred in people who had b

233 Well into the 21st century, we still triage acute myocardial infarction on the basis of the presence

234 alyzed Medicare data on hospitalizations for acute myocardial infarction or cardiac arrest among Medi

235 admitted to marathon-affected hospitals with acute myocardial infarction or cardiac arrest on maratho

236 onist, in patients with ST-segment-elevation acute myocardial infarction or heart failure with reduce

237 ws: principal HF hospitalizations; principal acute myocardial infarction or pneumonia hospitalization

238 n myocardial strain imaging in patients with acute myocardial infarction or stable ischemic heart dis

239 hospital admission with, or mortality from, acute myocardial infarction or stroke.

240 are characteristics of patients suffering an acute myocardial infarction or undergoing cardiovascular

241 Patients with a history of PCI or CABG, acute myocardial infarction, or an indication for concom

242 was the composite of incident heart failure, acute myocardial infarction, or cardiovascular death.

243 ticipants were diagnosed with heart failure, acute myocardial infarction, or cardiovascular death.

244 ncipal discharge diagnosis of heart failure, acute myocardial infarction, or pneumonia and estimated

245 eneficiaries hospitalized for heart failure, acute myocardial infarction, or pneumonia, reductions in

246 -AMI OUTCOME CMR (Stem Cells Mobilization in Acute Myocardial Infarction Outcome Cardiac Magnetic Res

247 for acute nonischemic myocardial injury and acute myocardial infarction, particularly type 2 myocard

248 arch Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) is

249 arch Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) reg

250 arch Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status).

251 a rigorously imaging-based selected group of acute myocardial infarction patients, with detailed safe

252 The elevated risk of heart failure and acute myocardial infarction persisted in subgroup analys

253 prescribed to frail, older adults following acute myocardial infarction, potentially because of the

254 Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction [PRAGUE-18]; NCT02808767).

255 gene expression profiling at the time of an acute myocardial infarction provides information concern

256 aker/implantable cardioverter defibrillator, acute myocardial infarction, pulmonary embolism, stroke/

257 ncluding heart failure (r = 0.39; P < 0.01), acute myocardial infarction (r = 0.30; P < 0.01), pneumo

258 In a validation cohort of acute myocardial infarction, receiver operating characte

259 tial of Corrie as a self-management tool for acute myocardial infarction recovery.

260 270 admissions using temporary MCS, 33% had acute myocardial infarction-related cardiogenic shock (C

261 Acute myocardial infarction remains a leading cause of m

262 e with right coronary artery disease, recent acute myocardial infarction, renal dysfunction, and pati

263 I, 1.46 to 1.72) and a 40% increased risk of acute myocardial infarction (RR 1.40; 95% CI, 1.23 to 1.

264 c natural killer cell depletion 24 hours pre-acute myocardial infarction significantly improved infar

265 if they are 18 years or older, admitted with acute myocardial infarction (ST-segment-elevation myocar

266 uclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological in

267 tios (HR) for the composite outcome of AIDS, acute myocardial infarction, stroke, end-stage renal dis

268 ovascular mortality, coronary heart disease, acute myocardial infarction, stroke, heart failure, and

269 e risk of cardiovascular diseases, including acute myocardial infarction, stroke, peripheral artery d

270 MACE included hospitalization for acute myocardial infarction, stroke, transient ischemic

271 Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction) study did not find any sign

272 During Percutaneous Coronary Intervention in Acute Myocardial Infarction], TASTE [Thrombus Aspiration

273 rction contribute to the mortality burden of acute myocardial infarction, the share of these deaths t

274 64 for mortality among patients admitted for acute myocardial infarction to 2615 for mortality among

275 patients with subclinical hypothyroidism and acute myocardial infarction, treatment with levothyroxin

276 Clinical Evaluation of the Xience-V Stent in Acute Myocardial Infarction Trial).

277 Elderly patients with acute myocardial infarction undergoing percutaneous coro

278 Four strategies for very early rule-out of acute myocardial infarction using high-sensitivity cardi

279 LTS We identified all patients admitted with acute myocardial infarction using the California State I

280 emia, coagulopathy, obesity, major bleeding, acute myocardial infarction, vascular complications, and

281 additional criteria required for spontaneous acute myocardial infarction versus those patients who do

282 m) required for the diagnosis of spontaneous acute myocardial infarction versus those that did.

283 s the case-fatality rate of patients in whom acute myocardial infarction was a primary diagnosis.

284 Acute myocardial infarction was diagnosed in the first p

285 hin the 28 days preceding death, and whether acute myocardial infarction was one of the recorded diag

286 Among 2828 enrolled patients, acute myocardial infarction was the final diagnosis in 4

287 ire administered 30 days after discharge for acute myocardial infarction, wherein higher scores repre

288 ot been clearly established in patients with acute myocardial infarction who are undergoing percutane

289 PCI rates and in mortality for patients with acute myocardial infarction who did not undergo PCI.

290 ne oxygen therapy in patients with suspected acute myocardial infarction who do not have hypoxemia at

291 ranslation into treatments for patients with acute myocardial infarction, who typically are of advanc

292 ents (57 years +/- 12; 78% men) with a first acute myocardial infarction, who were prospectively enro

293 This study recruited 3,959 patients with acute myocardial infarction with a median and minimum fo

294 In patients who have acute myocardial infarction with cardiogenic shock, earl

295 had multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, the

296 distinct kinetics for PCSK6 in patients with acute myocardial infarction, with a peak on postinfarcti

297 s been investigated in patients suffering an acute myocardial infarction, with the final aim of salva

298 s were used to identify all patients with an acute myocardial infarction within these states.

299 r Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02

300 ) and by qualifying event type (range: 7.1% [acute myocardial infarction without procedure] to 55.3%